Patent · US Active

Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions

US11369691B2 · kind B2 · utility

10Cited by

51References

19Claims

0Family size

Assignee

CureVac AG · DE

Inventors

Florian Von Der Mülbe · Stuttgart, DE
Ingmar Hoerr · Tübingen, DE
Steve Pascolo · Tübingen, DE

Key dates

Filing date	Jan 25, 2016
Grant date	Jun 28, 2022
Priority date	—
Expiry date	Apr 30, 2038

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilisation and translational efficiency of modified mRNA of the invention.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.